These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 10775736)

  • 1. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group.
    Versi E; Appell R; Mobley D; Patton W; Saltzstein D
    Obstet Gynecol; 2000 May; 95(5):718-21. PubMed ID: 10775736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group.
    Anderson RU; Mobley D; Blank B; Saltzstein D; Susset J; Brown JS
    J Urol; 1999 Jun; 161(6):1809-12. PubMed ID: 10332441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships.
    Gupta SK; Sathyan G; Lindemulder EA; Ho PL; Sheiner LB; Aarons L
    Clin Pharmacol Ther; 1999 Jun; 65(6):672-84. PubMed ID: 10391673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth.
    Corcos J; Casey R; Patrick A; Andreou C; Miceli PC; Reiz JL; Harsanyi Z; Darke AC;
    BJU Int; 2006 Mar; 97(3):520-7. PubMed ID: 16469019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group.
    Gleason DM; Susset J; White C; Munoz DR; Sand PK
    Urology; 1999 Sep; 54(3):420-3. PubMed ID: 10475346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence.
    Davila GW; Daugherty CA; Sanders SW;
    J Urol; 2001 Jul; 166(1):140-5. PubMed ID: 11435842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
    Diokno AC; Appell RA; Sand PK; Dmochowski RR; Gburek BM; Klimberg IW; Kell SH;
    Mayo Clin Proc; 2003 Jun; 78(6):687-95. PubMed ID: 12934777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.
    Gupta SK; Sathyan G
    J Clin Pharmacol; 1999 Mar; 39(3):289-96. PubMed ID: 10073329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.
    Zellner M; Madersbacher H; Palmtag H; Stöhrer M; Bödeker RH;
    Clin Ther; 2009 Nov; 31(11):2519-39. PubMed ID: 20109997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
    Appell RA; Sand P; Dmochowski R; Anderson R; Zinner N; Lama D; Roach M; Miklos J; Saltzstein D; Boone T; Staskin DR; Albrecht D;
    Mayo Clin Proc; 2001 Apr; 76(4):358-63. PubMed ID: 11322350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence.
    Barkin J; Corcos J; Radomski S; Jammal MP; Miceli PC; Reiz JL; Harsanyi Z; Darke AC;
    Clin Ther; 2004 Jul; 26(7):1026-36. PubMed ID: 15336467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
    Herschorn S; Stothers L; Carlson K; Egerdie B; Gajewski JB; Pommerville P; Schulz J; Radomski S; Drutz H; Barkin J; Paradiso-Hardy F
    J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which anticholinergic drug for overactive bladder symptoms in adults.
    Hay-Smith J; Herbison P; Ellis G; Morris A
    Cochrane Database Syst Rev; 2005 Jul; (3):CD005429. PubMed ID: 16034974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolterodine: a clinical review.
    Crandall C
    J Womens Health Gend Based Med; 2001 Oct; 10(8):735-43. PubMed ID: 11703885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence.
    Reinberg Y; Crocker J; Wolpert J; Vandersteen D
    J Urol; 2003 Jan; 169(1):317-9. PubMed ID: 12478180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary evaluation of a new controlled-release oxybutynin in urinary incontinence.
    Radomski SB; Caley B; Reiz JL; Miceli PC; Harsanyi Z; Darke AC
    Curr Med Res Opin; 2004; 20(2):249-53. PubMed ID: 15006020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-release oxybutynin.
    Comer AM; Goa KL
    Drugs Aging; 2000 Feb; 16(2):149-55; discussion 156-7. PubMed ID: 10755330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials.
    Armstrong RB; Dmochowski RR; Sand PK; Macdiarmid S
    Int Urol Nephrol; 2007; 39(4):1069-77. PubMed ID: 17333521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
    Goldenberg MM
    Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence.
    Dmochowski RR; Davila GW; Zinner NR; Gittelman MC; Saltzstein DR; Lyttle S; Sanders SW;
    J Urol; 2002 Aug; 168(2):580-6. PubMed ID: 12131314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.